Goldman, Butterwick, Fitzpatrick and Groff Report issue

Academic/Hospital Phase 4

Organization Overview

First Clinical Trial
2015
NCT02446223
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

DCLA | Goldman, Butterwick, Fitzpatrick and Groff